Element Biosciences introduced Vitari, its first high‑throughput sequencer that produces roughly 3 terabases per paired‑end 150 bp run in 36 hours and aims to drive the cost of a 30X human genome toward $100. The platform targets research and large‑scale sequencing centers by promising high throughput and lower per‑genome economics. Element pitches Vitari as a disruptive alternative in a market long dominated by incumbents, potentially altering economics for population genomics, clinical sequencing and large‑cohort studies. The company highlights run speed and throughput as key levers for scaling genomic projects and reducing bottlenecks in data generation. Investors and customers will test whether Vitari’s claimed costs and throughput translate into validated performance and durable supply chain advantages.